Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00492388 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients
A Phase 3 study, sponsored by Hospira, now a wholly owned subsidiary of Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2
- Enrollment target
NCT00492388 is a Phase 3 study that was terminated before completion, run by Hospira, now a wholly owned subsidiary of Pfizer. The registered enrollment target is 2 participants.
The verdict
NCT00492388, a Phase 3 study, was terminated before completion, sponsored by Hospira, now a wholly owned subsidiary of Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2 participants
- Enrollment target
Study Summary
To assess the safety and efficacy of PMI-150 (Intranasal Ketamine) as an analgesic for the treatment of breakthrough pain in cancer patients.
Interventions
- DRUG placebo
- DRUG PMI-150 (intranasal ketamine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2007-06 |
| Est. Completion | 2011-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00492388
The ClinicalTrials.gov registry entry for NCT00492388 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hospira, now a wholly owned subsidiary of Pfizer, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00492388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00492388 about?
NCT00492388 is a clinical study titled "Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients". To assess the safety and efficacy of PMI-150 (Intranasal Ketamine) as an analgesic for the treatment of breakthrough pain in cancer patients.
What is the current status of trial NCT00492388?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2 participants. The study started on 2007-06. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00492388?
The interventions under investigation include: placebo (DRUG), PMI-150 (intranasal ketamine) (DRUG).
Who is sponsoring clinical trial NCT00492388?
This trial is sponsored by Hospira, now a wholly owned subsidiary of Pfizer, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.